Hormone Replacement Therapy for Menopause Indication Market Size (2022 – 2030)

According to our research report, in  2022, the Global Hormone Replacement Therapy for Menopause Indication Market was valued at USD 30.46 million and is projected to reach a market size of USD 45 million by 2030. Over the forecast period of 2023-2030, the market is projected to grow at a CAGR of 5%. 

Industry Overview

When the body is unable to produce enough natural hormones, hormone replacement therapy (HRT) is used to address the condition. For instance, thyroid and human growth hormone patients may receive hormone replacement treatment. Additionally, HRT was frequently administered to menopausal women for the prevention of osteoporosis as well as the relief of symptoms such as hot flashes, night sweats, sleep disturbances, psychological issues, and genito-urinary issues (urinary frequency and vaginal dryness). In addition, the poll of 2,000 American women between the ages of 30 and 60 revealed that roughly 47% of the population has dealt with the signs of a hormone imbalance in 2019.

The prevalence of menopausal disorders is on the rise, and women are becoming more aware of the problems associated with post-menopause, which are two key contributors to the expansion of the global market for hormone replacement therapy. New launches of hormone replacement therapy are also anticipated to make a significant contribution to the expansion of the hormone replacement therapy market. However, throughout the projected period, it is anticipated that the negative effects of hormone replacement therapy and the high cost of treatment will restrain market expansion. The development of bioidentical hormone replacement treatment and the use of telemedicine for hormone replacement therapy, on the other hand, are anticipated to create lucrative opportunities for the expansion of the worldwide hormone replacement therapy market shortly.

5,451 COVID cases associated with HRT (estrogen therapy treatment) experienced a 78 % decrease in infection and mortality rate, according to a study conducted by the Oxford-Royal College of General Practitioners Research and Surveillance Centre on 1.8 million medical records of women from 465 general practitioners. Males typically have more serious infections, greater hospitalization and fatality rates, and more severe infections overall.

Impact of Covid-19 on the industry

In late December, the coronavirus (COVID-19) was found in the Chinese city of Wuhan's Hubei province. A virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that spreads from person to person is the cause of the illness. The market for hormone replacement therapy has been adversely affected by the adoption of lockdown. The new coronavirus also exhibits a broad range of clinical manifestations, severity, and mortality rates. Additionally, reproductive treatment after menopause has been impacted by the pandemic because of data indicating that declining estrogen levels could put older women at risk for the illness and that hormone withdrawal could hasten the progression of COVID-19.

The administration of estradiol through a transdermal patch for a brief period—7 days—will be used in phase 2 clinical research started by Stony Brook University in April 2020 to examine the function of estrogen in lowering the severity of COVID-19 symptoms in comparison to standard therapy. As a result of the aforementioned causes, hormone replacement therapy is anticipated to play a promising role in the development of innovative medicines for the efficient treatment of SARS-CoV2 virus infection, which may cause the studied market to expand during the pandemic.

Market Drivers

Increasing awareness about hormone deficiency will drive the market growth

Growing public awareness of hormone deficiencies and diseases is anticipated to fuel market expansion. For instance, the UK-based non-governmental organization Child Growth Foundation supports individuals with uncommon growth hormone problems. To enhance patients' quality of life, this group offers information and support to patients, carers, and medical professionals.

Increasing research and development in the industry will drive the market growth

New goods are being introduced to the market as a result of key firms' growing involvement in the development of novel medicines. For instance, Ascendis Pharma A/S gained market clearance from the European Commission in January 2022 for their medicine SKYTROFA, which is used to treat growth hormone abnormalities in children and adolescents. This medicine is the first once-weekly therapy for pediatric growth hormone insufficiency.

Combination Hormone Replacement Therapy Associated with Cancer

Hormone replacement treatment use can promote the growth of malignant cells.

Even if administered for a brief period, combined hormone replacement therapy (combination of progesterone and estrogen) can raise the risk of breast cancer by 75%. The U.S. Women's Health Initiative claims that using combination hormone replacement treatment increases the risk of developing ovarian and uterine cancer, among other cancers. This factor is anticipated to limit the expansion in the use of hormone replacement treatment in the ensuing years. Blood clots, cardiac issues, and other conditions linked to hormone replacement treatment are also anticipated to hurt the market's expansion.

Market Restraints

The high cost associated with the therapy will challenge the market growth

The expensive expense of hormonal replacement therapy treatment, however, may limit market expansion. For instance, the annual cost of hormone replacement treatment injections ranges from USD 288 to USD 1,440 for patients with insurance and from USD 480 to USD 4,800 for those without insurance.

HORMONE REPLACEMENT THERAPY FOR MENOPAUSE INDICATION MARKET REPORT COVERAGE:

This research report on the global hormone replacement therapy for menopause market has been segmented and sub-segmented based on, and Geography & region.

Global Hormone Replacement Therapy for Menopause Indication- By Product Type

• Estrogen and Progesterone Replacement Therapy
• Human Growth Hormone (HGH) Replacement Therapy
• Thyroid Hormone Replacement Therapy
• Testosterone Replacement Therapy
• Parathyroid Hormone Replacement

The HRT market is divided based on product into testosterone replacement therapy, thyroid replacement therapy, parathyroid hormone replacement therapy, and estrogen and progesterone replacement therapy. In 2021, the sector for estrogen and progesterone replacement therapy had the biggest market share, with 53.15 %. An increase in the number of women experiencing menopause was blamed for the dominance. The American Congress of Obstetricians and Gynecologists estimates that 6,000 women in the United States go through menopause every day. Due to rising incidence and more product penetration, the parathyroid hormone replacement market is anticipated to develop at the quickest rate throughout the forecast period. The National Organization for Rare Disease's 2021 database estimates that 70,000 Americans have hypoparathyroidism. In the section on parathyroid hormone, only one product has been approved, i.e., Natpara.

Global Hormone Replacement Therapy for Menopause Indication- By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

The HRT market is divided into oral, parenteral, transdermal, and other segments based on the route of administration. Because it is so easily administered and has a high prescription rate, the oral segment dominated the market in 2021. Tablets and pills are typically included in HRT medicines. During the projected time, the parenteral segment is anticipated to have profitable expansion. The category is estimated to grow as a result of improvements in parenteral drug delivery techniques, such as pen-based medication delivery, which are estimated to increase patient compliance and simplify administration. The Humatrope HumatroPen, Norditropin FlexPro Pen, and Genotropin Mixer Pen are a few of the well-known items offered in pen form.

In addition, the introduction of a new long-acting growth hormone injectable is anticipated to stimulate segment expansion. For instance, the Ministry of Health, Labour and Welfare of Japan granted permission for the commercialization of NGENLA to treat growth hormone problems in January 2022 to Pfizer, Inc. and OPKO Health, Inc. With a once-weekly treatment frequency, this product is the next-generation long-acting growth hormone injection.

Global Hormone Replacement Therapy for Menopause Indication- By Geography & Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

With a share of 37.54 % in the global market for hormone replacement treatment in 2021, North America led the way and is projected to continue dominating during the forecast period. The biggest market share in the area is a result of several reasons, including significant product launches, manufacturer collaboration agreements, and benevolent reimbursement policies. For instance, Novo Nordisk A/Sogroya S's (somapacitan-beco), a medication for HGH replacement therapy, received FDA approval in August 2020. When an adult is diagnosed with a growth hormone shortage, this medication is given subcutaneously once a week.

According to estimates, the region with the quickest growth will be the Asia-Pacific. In women in East Asian nations, the prevalence of vasomotor symptoms related to menopause has been found to range from 43% to 83 %, according to the Journal of the North American Menopause Society (May 2022). Thus, it is anticipated that the region's demand for hormone replacement therapy will increase as more women enter menopause.

Global Hormone Replacement Therapy for Menopause Indication- By Companies

1. Eli Lilly and Company
2. Bayer AG
3. Noven Pharmaceuticals, Inc.
4. Pfizer Inc.
5. Merck & Co., Inc.
6. Viatris, Inc.
7. Novo Nordisk A/S
8. F. Hoffmann-La Roche Ltd.
9. ASCEND Therapeutics US, LLC.
10. AbbVie, Inc.

NOTABLE HAPPENINGS IN THE GLOBAL HORMONE REPLACEMENT THERAPY FOR MENOPAUSE INDICATION MARKET IN THE RECENT PAST:

• Regulatory Approval: - In 2022, the Ministry of Health, Labour and Welfare of Japan granted permission for the commercialization of NGENLA to treat growth hormone problems to Pfizer, Inc.
• Regulatory Approval: - In 2020, Novo Nordisk A/Sogroya S's (somapacitan-beco), a medication for HGH replacement therapy, received FDA approval.
• Regulatory story Approval: - In 2022, Ascendis Pharma A/S gained market clearance from the European Commission for their medicine SKYTROFA, which is used to treat growth hormone abnormalities in children and adolescents.